Compare · BDX vs IVF
BDX vs IVF
Side-by-side comparison of Becton Dickinson and Company (BDX) and INVO Fertility Inc. (IVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IVF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 19407.8x IVF ($2.7M).
- Over the past year, BDX is up 3.4% and IVF is down 99.0% - BDX leads by 102.4 points.
- BDX has been more active in the news (9 items in the past 4 weeks vs 2 for IVF).
- BDX has more recent analyst coverage (25 ratings vs 0 for IVF).
- Company
- Becton Dickinson and Company
- INVO Fertility Inc.
- Price
- $191.68-1.09%
- $0.56+1.27%
- Market cap
- $52.78B
- $2.7M
- 1M return
- +5.72%
- -41.31%
- 1Y return
- +3.42%
- -99.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest IVF
- Amendment: SEC Form SCHEDULE 13G/A filed by INVO Fertility Inc.
- INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
- SEC Form S-8 filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Regulation FD Disclosure
- INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
- INVO Fertility Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
- SEC Form 10-Q filed by INVO Fertility Inc.
- SEC Form 424B3 filed by INVO Fertility Inc.